ROCK ISLAND, IL (02/17/2010)(readMedia)-- Four professors and nearly 40 Augustana students will leave in early March to spend 10 weeks studying in the West African countries of Ghana and Senegal. The two countries, both important regional and continental leaders, were chosen for the global learning experience because of their diverse culture, linguistic and topographical contrasts.

The term begins with six weeks in the country of Ghana, where the group will visit the capital city of Accra, as well as Kumasi and Cape Coast. The final four weeks will be in Dakar and St. Louis in Senegal. Classes will be held four days a week and cover the topics of African history, literature, music and art through reading, assignments, guest lectures and field trips. Students will also volunteer at a school and orphanage, spend a weekend with a host family and visit and attend classes at local universities.

From your area, this includes:

Kevin Carton, a senior from Moline, IL majoring in speech communication, French, and Africana studies.

Crystina Mayfield, a sophomore from Coal Valley, IL majoring in general studies.

Bret VanDeWoestyne, a senior from Silvis, IL majoring in biology.

History professor Dr. Todd Cleveland hopes students will embrace the African culture during the term. "I'd like to think that simple things like taking local transportation, sampling new food at an informal food stall...will ultimately offer more insight into local culture and day-to-day living than will our sensational experiences, such as sleeping out in tents in the desert or swimming in the warm waters off the West African coast," said Cleveland.

Junior biology major Amanda Van Daalen of Waverly, Iowa, agrees the experience is an opportunity for personal change. "I see myself too often taking advantage of things that some people could only dream of. I want to have my eyes open to a new culture and I want to live in a culture where simple things are valued."

Co-director Dr. John Tawiah-Boateng said students have been attending a seminar since fall to prepare for the term away. "I hope as they experience a different lifestyle and culture they will compare realities and stereotypes that they see in movies or television."

All four professors, Tawiah-Boateng, Cleveland, art professor Dr. Rowen Schussheim-Anderson and music professor Dr. John Pfautz will teach a class during the term. Tawiah-Boateng, a native of Ghana, and Schussheim-Anderson helped initiate the first Ghana international term at Augustana in 2006, and now serve as co-directors of this trip. Cleveland and Pfautz have also previously traveled or researched in Africa. The students and professors will return to the United States in mid-May.

Several of the students will keep a blog of their adventures on Augustana's Globablogs. To read more about their trip, go to www.augustana.edu/blogs/international.

For additional information, contact Kamy Beattie, Director of Public Relations at kamybeattie@augustana.edu or (309) 794-7721.

About Augustana: Founded in 1860 and situated on a 115-acre campus near the Mississippi River, Augustana College is a private, liberal arts institution affiliated with the Evangelical Lutheran Church in America (ELCA). The college enrolls nearly 2,500 students from diverse geographic, social, ethnic and religious backgrounds and offers more than 60 majors and related areas of study. Augustana employs 226 faculty and has a student-faculty ratio of 11:1. Augustana continues to do what it has always done: challenge and prepare students for lives of leadership and service in our complex, ever-changing world.

WASHINGTON --- Senator Chuck Grassley is asking the Food and Drug Administration for an update on the implementation of new guidelines for medical device makers on when they need to file new information with the agency and seek clearance for the marketing and use of modified devices under the 510(k) system, the agency's less stringent process for reviewing most medical devices.

Grassley said that his inquiry today follows up on questions he asked more than a year ago, after a ring used in heart-valve repair was being implanted in patients even though the device hadn't been cleared for this purpose by the FDA.  The FDA subsequently told Grassley that its current policy was inadequate and that an update was underway.  Grassley also asked a number of questions today about the FDA's requirements for manufacturers to report changes made to FDA-approved devices.

"My questions are aimed at establishing greater transparency and accountability for doctors and their patients," Grassley said.  "People have a right to know exactly what the FDA has approved, or not, in making decisions about their health care.  For this to happen, the FDA's policies need to be effective in establishing an accurate public record about the FDA-approval status of any particular product."

The text of the letter sent today from Grassley to the FDA Commissioner follows here.

February 16, 2010

The Honorable Margaret A. Hamburg

Commissioner

U.S. Food and Drug Administration

10903 New Hampshire Ave.

Silver Spring, MD 20993

Dear Commissioner Hamburg:

The United States Senate Committee on Finance (Committee) has jurisdiction over, among other things, the Medicare and Medicaid programs.  As Ranking Member of the Committee, I have a responsibility to the more than 100 million Americans who receive health care coverage under these programs to oversee their proper administration and ensure that taxpayer dollars are appropriately spent on safe and effective drugs and devices.

I appreciate your response of September 30, 2009, to my questions regarding the Food and Drug Administration's (FDA or Agency) guidance to manufacturers on when a modification to a device requires the filing of a new 510(k).  Over a year ago, I wrote to the FDA regarding serious allegations that an annuloplasty ring used in heart valve repair was being implanted in patients even though the device was allegedly not cleared for marketing by the FDA.  The FDA concluded that the company had made the wrong decision when it marketed the product without first seeking clearance from the Agency.  That device, the Myxo dETlogix Annuloplasty Ring (dETlogix ring), has since been cleared by the FDA, but as I stated in my letter to the FDA last April, the fact remains that for more than two years, patients at Northwestern Memorial Hospital were being implanted with the device before a 510(k) was submitted to the Agency.

I also wrote to Northwestern Memorial Healthcare and Northwestern University in September regarding the same allegations and asked them whether or not they obtain assurances or confirmation from a device manufacturer that a device is FDA-approved before it is used in their facilities. Attached are their responses for your consideration.  Northwestern Memorial Healthcare stated in its response that Edwards Lifesciences assured Dr. McCarthy that it was taking the steps necessary for FDA approval.  It also stated that, "the health care provider relies on the manufacturer to provide timely and accurate information regarding the regulatory status of the device."  However, in this case, the manufacturer followed FDA's guidance and made the wrong decision regarding its device.

In your September response, you stated that FDA believes its current policy on when a modification to a device requires a new 510(k) submission is not sufficiently clear and is revising the guidance document.  I agree that the guidance document needs to be revised so that we can prevent similar events from occurring in the future.  However, it has been more than four months since I received your response and the new guidance has yet to be released.  Accordingly, I would appreciate you advising me immediately on the status of FDA's revisions to the Agency's guidance entitled, "Deciding When to Submit a 510(k) for a Change to an Existing Device."

In addition, it is my understanding that device manufacturers registered with the FDA must also list the devices that they make with the Agency.  According to FDA's website, registration information must be submitted each year between October 1 and December 31 even if no changes have occurred, and at that time listing information should be reviewed as well.  The website also states that a manufacturer can access the FDA Unified Registration and Listing System at any time to update changes to their registration and listing information as the changes occur.  Examples provided by the FDA include a change to a previously listed device or the introduction of another device into commercial distribution.  In light of the statements made on FDA's website please respond to the following questions:

1)         Would a manufacturer be required to update its device listings even if it changed only the name of an existing device?

2)         Would the manufacturer also be required to update its listings if it made a modification to a device that did not require submission of a new 510(k) but marketed that device under a different name?

3)         If the answer to either question is no, please explain why not.  Please also explain how patients and their doctors would obtain information about the status of a device other than from the manufacturer itself.

4)         FDA concluded that Edwards Lifesciences' dETlogix ring did require a new 510(k).  However, even if a new 510(k) had not been required, was the company required to list that device with the FDA?

Thank you for your attention to this important matter.  I would appreciate a response to the requests set forth in this letter by no later than March 2, 2010.

Sincerely,

Chuck Grassley

United States Senator

Ranking Member of the Committee on Finance